Effective Management of Acute Respiratory Infections: The Role of Combined Oral and Nebulized Sobrerol

Introduction

Acute respiratory infections often affect the upper airways and are mostly viral. The common cold is the main example of acute upper respiratory infections (AURI). It typically resolves within a few days but may leave a lingering cough for weeks. Some viral infections can lead to flu-like symptoms, which are similar to those of influenza.

In clinical practice, diagnostic tests for AURI are uncommon, making it difficult to differentiate between types of infections. However, common symptoms include nasal congestion, sore throat, and cough. Excessive mucus production can worsen infections and lead to further illness. Therefore, managing mucus production is essential for patients with AURI.

Sobrerol is a muco-active drug available for over 50 years. It belongs to the mucolytics class and has a unique action. Sobrerol helps reduce mucus viscosity, increases ciliary movement, promotes mucociliary clearance, enhances surfactant phospholipid levels, encourages secretory IgA production, and has antioxidant properties. Sobrerol can be classified as a mucolytic-mucoregulator. Unlike other muco-active agents, sobrerol also stimulates the immune system.

Sobrerol is available in various formulations, including syrup and granules. It is primarily indicated for treating respiratory diseases with thick mucus. Recommended dosages vary; for adults, it’s 600 mg daily for up to three days, and for children, the dose is halved. It is contraindicated for children under 30 months and those with certain medical conditions, such as epilepsy.

The revised recommendation limits sobrerol treatment to three days. To prolong its effectiveness, a combination of oral and nebulized sobrerol has been explored. This study compares the effectiveness of three different sobrerol administration methods: oral, nebulization, and combined.

Materials and Methods

Study Design

This observational study took place in various regions of Italy. It followed the Helsinki Declaration and received independent Review Board approval. Patient consent was not needed, as data collection was anonymous.

Five pediatricians and five general practitioners collected data from patients treated during the autumn-spring of 2023/24. They aimed to assess therapeutic options for respiratory infections. Patients were monitored through medical visits or telemedicine.

Inclusion criteria included patients over three years old with a history of frequent respiratory infections. Each doctor prescribed sobrerol and included a control group receiving standard treatment defined by the physician, typically involving antibiotics or anti-inflammatory drugs. Exclusions applied to younger children and those with specific health conditions.

Patients used four treatment options:

• Standard Therapy (ST) group: only standard treatment.
• Oral Sobrerol (OS) group: sobrerol syrup or sachets taken twice daily for three days.
• Nebulized Sobrerol (NS) group: sobrerol via nebulization twice daily.
• Combined Sobrerol (CS) group: both oral and nebulized sobrerol once daily.

Patients started therapy at infection onset using telemedicine for self-monitoring via visual analog scale (VAS) assessments. Doctors collected clinical data at onset, and again on day four and seven.

Statistical Analysis

Data from 177 patients were analyzed. The groups showed no significant differences in demographics.

Results

Findings indicated no significant differences in total respiratory infections among groups. However, there were notable differences in the presence and intensity of symptoms. At Day 4, combined sobrerol had a higher likelihood of reducing cough (Odds Ratio 15.2) and nebulized sobrerol significantly reduced nasal symptoms (Odds Ratio 6.7). At Day 7, combined sobrerol continued to show associations with the disappearance of cough (Odds Ratio 4.47) and nasal symptoms (Odds Ratio 3.2).

Graphs illustrated the improvement in symptoms, with combined sobrerol exhibiting the highest benefits.

Discussion

Respiratory infections pose significant burdens on patients and society. They often manifest as the common cold but can lead to complications like rhinosinusitis. Symptoms usually last a few days, and cough can persist, affecting life quality.

Sobrerol is a muco-active agent that manages symptoms by balancing mucus production. This study showed that combined oral and nebulized sobrerol effectively reduced cough and nasal symptoms after four and seven days.

While promising, the study faced limitations, such as its retrospective design and lack of control over patient selection. A larger sample size and randomized control trials would strengthen the findings and help compare combined sobrerol with current treatments.

Conclusion

This study suggests that a three-day combined course of oral and nebulized sobrerol may be effective for managing cough in patients with acute upper respiratory infections. Further studies are needed to confirm these findings.